AUROBINDO

PRESS RELEASE

24th February 2011

Aurobindo Pharma receives USFDA tentative approval for Venlafaxine Extended Release Capsules

Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US Food & Drug Administration to manufacture and market Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg.

Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg are the generic equivalent of Wyeth Pharmaceuticals Inc's Effexor® XR Capsules 37.5mg, 75mg and 150mg. Venlafaxine Hydrochloride Extended-release Capsules are indicated for the treatment of major depressive disorder (MDD) and falls under the Neurological (CNS) therapeutic category. The product has a market size of approximately US$ 2.4 Billion for the twelve months ending September 2010 according to IMS.

The tentatively approved ANDA No. 200834 for Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg was filed with Paragraph IV certification and is currently under litigation in the United States District Court for the District of New Jersey [Wyeth LLC v. Aurobindo Pharma Limited, and Aurobindo Pharma USA Inc., Civil Action No. 10-CV-02084]. The product will be launched after the litigation settlement.

Aurobindo now has a total of 132 ANDA approvals (99 Final approvals and 33 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com